Drug Overview
Kyprolis (carfilzomib; Amgen/Ono Pharmaceutical) is a second-generation proteasome inhibitor that irreversibly binds to the N-terminal threonine-containing active sites of the 20S proteasome, the proteolytic core particle within the 26S proteasome.
The proteasome is a cellular complex that breaks down proteins; it is believed to play a critical role in the degradation (and therefore regulation) of a number of proteins involved in the regulation of cell cycle, apoptosis, and angiogenesis. In vitro, Kyprolis has shown antiproliferative and proapoptotic activity in both solid and hematologic tumor cells. In animal studies, it was shown to inhibit proteasome activity and delay tumor growth in models of multiple myeloma, hematological malignancies, and solid tumors.
Kyprolis (carfilzomib; Amgen/Ono Pharmaceutical) is a second-generation proteasome inhibitor that irreversibly binds to the N-terminal threonine-containing active sites of the 20S proteasome, the proteolytic core particle within the 26S proteasome.
The proteasome is a cellular complex that breaks down proteins; it is believed to play a critical role in the degradation (and therefore regulation) of a number of proteins involved in the regulation of cell cycle, apoptosis, and angiogenesis. In vitro, Kyprolis has shown antiproliferative and proapoptotic activity in both solid and hematologic tumor cells. In animal studies, it was shown to inhibit proteasome activity and delay tumor growth in models of multiple myeloma, hematological malignancies, and solid tumors.
Table of Contents
OVERVIEWDrug Overview
Product Profiles
Kyprolis : Multiple myeloma
Kyprolis : NHL: Mantle cell lymphoma (MCL)
LIST OF FIGURES
Figure 1: Kyprolis for multiple myeloma – SWOT analysis
Figure 2: The authors drug assessment summary of Kyprolis for multiple myeloma
Figure 3: The authors drug assessment summary of Kyprolis for multiple myeloma
Figure 4: Kyprolis sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 5: Kyprolis for mantle cell lymphoma – SWOT analysis
LIST OF TABLES
Table 1: Kyprolis drug profile
Table 2: Kyprolis pivotal trial data in multiple myeloma
Table 3: Kyprolis late-phase trial data in multiple myeloma
Table 4: Kyprolis early-phase trial data in multiple myeloma
Table 5: Kyprolis ongoing Phase III trials in multiple myeloma
Table 6: Kyprolis sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 7: Patients treated with Kyprolis across the US, Japan, and five major EU markets, by country, 2017–26
Table 8: Kyprolis drug profile
Table 9: Kyprolis Phase I/II trials in mantle cell lymphoma
